Advertisement

Sepsis Definitions

  • Javier Pérez
  • R. Phillip Dellinger
Chapter
Part of the Perspectives on Critical Care Infectious Diseases book series (CCID, volume 2)

Abstract

Stedman’s medical dictionary defines sepsis as “the presence of various pus-forming and other pathogenic organisms, or their toxins, in the blood or tissues” (1).

Keywords

Septic Shock Severe Sepsis Organ Dysfunction Systemic Inflammatory Response Syndrome Consensus Conference 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stedman’s Medical Dictionary. 26th edition. Williams and Wilkins. Baltimore 1995.Google Scholar
  2. 2.
    Kreger BE, Craven DE, McCabe WR. Gram-negative bacteremia. Reevaluation of clinical features and treatment in 612 patients. Am J Med 1980;68: 344–355.PubMedCrossRefGoogle Scholar
  3. 3.
    Ziegler EJ, McCutchan JA, Fierer J, Glauser MP, Sadoff JC, Douglas H, Braude AI. Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Eng J Med 1982;307: 1225–1230.CrossRefGoogle Scholar
  4. 4.
    Poole GV, Griswald JA, Mukkassa FF. Sepsis and infection in the intensive care unit: are they related? Am Surg 1993;59: 60–64.PubMedGoogle Scholar
  5. 5.
    Sibbald WJ, Marshall J, Christou N and the Canadian Multiple Organ Failure Study Group. “Sepsis”: clarity of existing terminology… or more confusion? Crit Care Med 1991;19: 996–998.PubMedCrossRefGoogle Scholar
  6. 6.
    Bossink AWJ, Groeneveld J, Hack EC, Thijs LG. Predictor of mortality in febrile medical patients. How useful are “SIRS” and sepsis criteria? Chest 1998;113: 1533–1541.PubMedCrossRefGoogle Scholar
  7. 7.
    Bone RC, Fisher CJ, Clemmer TP, Slotman GJ, Metz CA, Balk RA. Sepsis syndrome: a valid clinical entity. Methylprednisolone Severe Sepsis Study Group. Crit Care Med 1989;17: 389–393.PubMedCrossRefGoogle Scholar
  8. 8.
    Sprung CL. Definitions of sepsis-Have we reached a consensus? Crit Care Med 1991;19:849–851.PubMedCrossRefGoogle Scholar
  9. 9.
    Parker MM, Parrillo JE. Septic shock: hemodynamics and pathogenesis. JAMA 1983;250:3324–3327.PubMedCrossRefGoogle Scholar
  10. 10.
    Members of the American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992;20:864–874.CrossRefGoogle Scholar
  11. 11.
    Knaus WA, Sun X, Nystrom O, Wagner DP. Evaluation of definitions for sepsis. Chest 1992;101: 1656–1662.PubMedCrossRefGoogle Scholar
  12. 12.
    Vincent J-L. Dear SIRS, I’m sorry to say that I don’t like you… Crit Care Med 1997;25:372–374.PubMedCrossRefGoogle Scholar
  13. 13.
    Abraham E, Matthay MA, Dinarello CA, Vincent JL, Cohen J, Opal S, Glauser M, Parsons P, Fisher CJ Jr., Repine JE. Consensus conference definitions for sepsis, septic shock, acute lung injury and acute respiratory distress syndrome: Time for a reevaluation. Crit Care Med 2000;28:232–235.PubMedCrossRefGoogle Scholar
  14. 14.
    Marshall JC, Sweeney D. Microbial infections and the septic response in critical surgical illness. Sepsis, not infection, determines outcome. Arch Surg 1990; 125:17–23.PubMedCrossRefGoogle Scholar
  15. 15.
    Dinarello CA. Interleukin-1 and the pathogenesis of the acute phase response. N Eng J Med 1984;311:1413–1418.CrossRefGoogle Scholar
  16. 16.
    Beutler B, Cerami A. Cachectin: more than a tumor necrosis factor. N Eng J Med 1987;316:379–385.CrossRefGoogle Scholar
  17. 17.
    Warters JM, Bessey PQ, Dinarello CA, Wolff SM, Wilmore DW. Both inflammatory and endocrine mediators stimulate host response to sepsis. Arch Surg 1986; 121:179–190.CrossRefGoogle Scholar
  18. 18.
    Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg 1976;184:333–341.PubMedCrossRefGoogle Scholar
  19. 19.
    Luce JM, Montgomery AB, Marks JD, Turner J, Metz CA, Murray JF. Ineffectiveness of high dose methyl-prednisolone in preventing parenchymal lung injury and improving mortality in septic shock. Am Rev Respir Dis 1988; 138:62–68.PubMedCrossRefGoogle Scholar
  20. 20.
    The Veterans administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of sepsis. N Eng J Med 1987;317:659–665.CrossRefGoogle Scholar
  21. 21.
    Bone RC, Fisher CJ, Clemmer TP. A controlled trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Eng J Med 1987;317:653–658.CrossRefGoogle Scholar
  22. 22.
    Sprung CL, Caralis PV, Marcial EG. The effects of high-dose corticosteroids in patients with septic shock: A prospective, controlled study. N Eng J Med 1984;311:1137–1143.CrossRefGoogle Scholar
  23. 23.
    Zeni F, Freeman B, Natanson C. Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 1997;25:1095–1100.PubMedCrossRefGoogle Scholar
  24. 24.
    Bone RC, Sibbald WJ, Sprung CL. The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 1992;101:1481–1483.PubMedCrossRefGoogle Scholar
  25. 25.
    Bone RC. Let’s agree on terminology: definitions of sepsis. Crit Care Med 1991;19:973–976.PubMedCrossRefGoogle Scholar
  26. 26.
    Dellinger RP, Bone RC. To SIRS with love. Crit Care Med 1998;26:178–179.PubMedCrossRefGoogle Scholar
  27. 27.
    Bone RC. Sepsis, sepsis syndrome, multi-organ failure: a plea for comparable definitions. Ann Intern Med 1991;114:332–333.PubMedGoogle Scholar
  28. 28.
    Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997;112:235–243.PubMedCrossRefGoogle Scholar
  29. 29.
    Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). JAMA 1995;273:117–123.PubMedCrossRefGoogle Scholar
  30. 30.
    Forceville X, Vitoux D, Gauzit R, Combes A, Lahilaire P, Chappuis P. Selenium, systemic immune response syndrome, sepsis and outcome in critically ill patients. Crit Care Med 1998;26:1536–1544.PubMedCrossRefGoogle Scholar
  31. 31.
    Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT Jr., Knaus WA, Levy H, Matuschak GM, Shanies HM, Taylor RW. Treatment of severe inflammatory response syndrome and sepsis with a novel bradykinin antagonist, Deltibant (CP-0127). JAMA 1997;277:482–487.PubMedCrossRefGoogle Scholar
  32. 32.
    Muckart DJJ, Bhagwanjee S. American College of Physicians/Society of Critical Care Medicine consensus conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med 1997;25:1789–1795.PubMedCrossRefGoogle Scholar
  33. 33.
    Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Int Care Med 1995;21:302–309.CrossRefGoogle Scholar
  34. 34.
    Bernard GR. Sepsis trials: intersection of investigation, regulation, funding and practice. Am J Respir Crit Care Med 1995; 152:4–10.PubMedGoogle Scholar
  35. 35.
    Sands KE, Bates DW, Lanken PA, Graman PS, Hibberd PL, Kahn KL, Parsonnet J, Panzer R, Oray EJ, Snydman DR. Epidemiology of sepsis syndrome in 8 academic medical centers. JAMA 1997;278:234–240.PubMedCrossRefGoogle Scholar
  36. 36.
    Dhainaut JF, Tenaillon A, Le Tulzo Y, Schlemmer B, Solet JP, Wolff M, Holzapfel L, Zeni F, Dreyfuss D, Mira JP. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994;22:1720–1728.PubMedGoogle Scholar
  37. 37.
    Fisher CJ, Slotman GJ, Opal SM, Pribble JP, Bone RC, Emmanuel G NgD, Bloedow DC, Catalano MA. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12–21.PubMedGoogle Scholar
  38. 38.
    Fisher CJ, Dhainaut JF, Opal SM, Pribble JP, Balk RA, Slotman GJ, Iberti TJ, Rackow EC, Shapiro MJ, Greenman RL, Reines D, Shelly MP, Thompson BW, LaBrecque JF, Catalano MA, Knaus WA, Sadoff JC. Recombinant human interleukins-1 receptor antagonist in the treatment of patients with sepsis syndrome. JAMA 1994;271:1836–1843.PubMedCrossRefGoogle Scholar
  39. 39.
    Abraham E, Wunderink R, Silverman H, Perl TM, Nasraway S, Levy H, Bone R, Wenzel RP, Balk R, Allred R, Pennington JE, Wherry JC. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha inpatients with sepsis syndrome: a randomized, controlled, double-blind, multicenter trial. JAMA 1995;273:934–941.PubMedCrossRefGoogle Scholar
  40. 40.
    Martin C, Boisson C, Haccoun M, Thomachot L, Mege JL. Patterns of cytokine evolution, tumor necrosis factor-alpha and interleukin-6 after septic shock, hemorrhagic shock and severe trauma. Crit Care Med 1997;25:1813–1819.PubMedCrossRefGoogle Scholar
  41. 41.
    Folkesson HG, Matthay MA, Hebert CA, Broaddus VC. Acid aspiration-induced lung injury in rabbits is mediated by interleukin-8 dependent mechanisms. J Clin Invest 1995;96:107–116.PubMedCrossRefGoogle Scholar
  42. 42.
    Moss M, Steinberg K, Guidot D, Duhon GF, Treece P, Wolken R, Hudson LD, Parsons PE. Diabetic patients with septic shock have decreased incidence of the acute respiratory distress syndrome (ARDS). Am J Respir Crit Care Med 1997;155:A503.Google Scholar
  43. 43.
    Wayte J, Silva AT, Krausz T, Cohen J. Observations on the role of tumor necrosis factor alpha in a murine model of shock due to Streptococcus pyogenes. Crit Care Med 1993;21:1207–1212.PubMedCrossRefGoogle Scholar
  44. 44.
    Reinhart K, Wiegand-Lohnert C, Grimminger F, Kaul M, Withington S, Treacher D, Eckart J, Willats S, Bouza C, Krausch D, Stockenhuber F, Eiselstein J, Daum L, Kempeni J. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996;24:733–742.PubMedCrossRefGoogle Scholar
  45. 45.
    Hack CE, DeGroot ER, Felt-Bersma RJF, Nuijens JH, Strack Van Schinjndel RJ, Eerenberg-Belmer AJ, Thijs LG, Aarden LA. In plasma levels of interleukin-6 in sepsis. Blood 1989;7:1704–1710.Google Scholar
  46. 46.
    Dinarello CA, Gelfland JA, Wolff SM. Anticytokine strategies in the treatment of systemic inflammatory response syndrome. JAMA 1993;269:1829–1835.PubMedCrossRefGoogle Scholar
  47. 47.
    Dellinger RP. Tumor necrosis factor in septic shock and multiple system trauma. Crit Care Med 1997;25:1771–1773.PubMedCrossRefGoogle Scholar
  48. 48.
    Strieter R, Kunkel S, Bone R. Role of tumor necrosis factor-alpha in disease states and inflammation. Crit Care Med 1993;21(suppl):S447–463.PubMedCrossRefGoogle Scholar
  49. 49.
    Roumen R, Hendriks T, van der Ven-Jongerkrisg J, Nieuwenhuijzen GA, Sauerwein RW, van der Meer JW, Goris RJ. Cytokine patterns in patients after major vascular surgery, hemorrhagic shock, and severe blunt trauma. Relation with subsequent adult respiratory distress syndrome and multiple organ failure. Ann Surg 1993;218:767–776.CrossRefGoogle Scholar
  50. 50.
    McClain C, Hill D, Schmidt J, Diehl AM. Cytokines and alcoholic liver disease. Semin Liver Dis 1993;13:170–182.PubMedCrossRefGoogle Scholar
  51. 51.
    Bell S, Chavali S, Bistrian B, Connolly CA, Utsunomiya T, Forse RA. Dietary fish oil and cytokine and eicosanoid production during human immunodeficiency virus infection. JPEN 1996;20:43–49.CrossRefGoogle Scholar
  52. 52.
    Brivet FG, Emilie D, Galanaud P. Pro-and anti-inflammatory cytokines during acute severe pancreatitis: and early and sustained response although unpredictable of death. Parisian Study group on acute pancreatitis. Crit Care Med 1999;27:749–755.PubMedCrossRefGoogle Scholar
  53. 53.
    Vincent JL, Bakker J, Marecaux G, Schandene L, Kahn RJ, Dupont E. Administration of anti-TNF antibody improves left ventricular function in septic shock patients: Results of a pilot study. Chest 1992;101:810–815.PubMedCrossRefGoogle Scholar
  54. 54.
    Abraham E, Glauser MP, Butler T, Garbino J, Gelmont D, Laterre PF, Kudsk K, Bruining HA, Otto C, Tobin E, Zwingelstein C, Lesslauer W, Leighton A. p55 tumor necrosis factor receptor fusion protein in the treatment of patients with severe sepsis and septic shock: a randomized controlled multicenter trial. JAMA 1997;277:1531–1538.PubMedCrossRefGoogle Scholar
  55. 55.
    Kushner I. C-reactive protein and the acute phase response. Hosp Pract 1990;25:13–28.Google Scholar
  56. 56.
    Chwals WJ, Fernandez M, Jamie A, Charles BJ, Rushing JT. Detection of postoperative sepsis in infants with the use of metabolic stress monitoring. Arch Surg 1994; 129:437–442.PubMedCrossRefGoogle Scholar
  57. 57.
    Shaw AC. Serum C-reactive protein and neopterin concentrations in patients with viral or bacterial infection. J Clin Pathol 1991;44:596–599.PubMedCrossRefGoogle Scholar
  58. 58.
    Yentis SM, Soni N, Sheldon J. C-reactive protein as a indicator of resolution of sepsis in the intensive care unit. Inten Care Med 1998;21:602–605.CrossRefGoogle Scholar
  59. 59.
    Provoa P, Almeida E, Moreira P, Fernandes A, Mealha R, Aragao A, Sabino H. C-reactive protein as an indicator of sepsis. Inten Care Med 1998;24:1052–1056.CrossRefGoogle Scholar
  60. 60.
    Ugarte H, Silva E, Mercan D, De Mendonca A, Vincent JL. Procalcitonin as a marker of infection in the intensive care unit. Crit Care Med 1999;27:498–504.PubMedCrossRefGoogle Scholar
  61. 61.
    Rau B, Steinbach G, Gansauge F, Mayer JM, Grunert A, Beger HG. The potential role of procalcitonin and interleukin-8 in the prediction of infected necrosis in acute pancreatitis. Gut 1997;41:832–840.PubMedCrossRefGoogle Scholar
  62. 62.
    Eberhard OK, Langefeld I, Kuse ER, Brunkhorst FM, Kliem V, Schlitt HJ, Pichlmayr R, Koch KM, Brunkhorst R. Procalcitonin in the early phase after renal transplantation-will it add to diagnostic accuracy? Clin Transplant 1998; 12:206–211.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2001

Authors and Affiliations

  • Javier Pérez
    • 1
  • R. Phillip Dellinger
    • 1
  1. 1.Rush-Presbyterian-St. Luke’s Medical Center ChicagoUSA

Personalised recommendations